SPOTLIGHT: Roche shutters trial

Roche has shuttered a heart transplant trial combining its immunosuppressant drug CellCept with sirolimus--an immunosuppressant sold by Wyeth as Rapamune--after seeing an unexpectedly high rate of organ rejection. Patients were switched from a combination of calcineurin inhibitor and CellCept. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.